Advertisement
Screener

OCULAR THERAPEUTIX, INC (OCUL) Selling and Marketing Expense

2.7 / 5 stars · 54/101 Roast Me

OCULAR THERAPEUTIX, INC Selling and Marketing Expense

OCULAR THERAPEUTIX, INC (OCUL) reported Selling and Marketing Expense of $17.28 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:SellingAndMarketingExpense · last filed 2026-08-03

  • OCULAR THERAPEUTIX, INC selling and marketing expense for the quarter ending 2026-06-30 was $17.28M, a 25.84% increase year-over-year.
  • OCULAR THERAPEUTIX, INC selling and marketing expense for the quarter ending 2026-03-31 was $16.58M, a 17.17% increase year-over-year.
  • OCULAR THERAPEUTIX, INC selling and marketing expense for the quarter ending 2025-12-31 was $12.96M, a 19.53% increase year-over-year.
  • OCULAR THERAPEUTIX, INC selling and marketing expense for the quarter ending 2025-09-30 was $13.09M, a 23.79% increase year-over-year.
  • OCULAR THERAPEUTIX, INC selling and marketing expense for fiscal 2025 was $53.92M, a 29.65% increase from fiscal 2024.
  • OCULAR THERAPEUTIX, INC selling and marketing expense for fiscal 2024 was $41.59M, a 2.57% increase from fiscal 2023.
  • OCULAR THERAPEUTIX, INC selling and marketing expense for fiscal 2023 was $40.55M, a 1.57% increase from fiscal 2022.
  • OCULAR THERAPEUTIX, INC selling and marketing expense for fiscal 2022 was $39.92M, a 13.45% increase from fiscal 2021.
Period endSelling and Marketing Expense 3 monthSelling and Marketing Expense 6 monthSelling and Marketing Expense 9 monthSelling and Marketing Expense 12 month
2026-06-30$17.28M
10-Q · filed 2026-08-03
$33.85M
10-Q · filed 2026-08-03
$46.81M
derived: sum of 3 quarters · filed 2026-08-03
$59.90M
derived: sum of 4 quarters · filed 2026-08-03
2026-03-31$16.58M
10-Q · filed 2026-05-05
$29.53M
derived: sum of 2 quarters · filed 2026-05-05
$42.62M
derived: sum of 3 quarters · filed 2026-05-05
$56.35M
derived: sum of 4 quarters · filed 2026-08-03
2025-12-31$12.96M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05
$26.05M
derived: sum of 2 quarters · filed 2026-02-05
$39.77M
derived: sum of 3 quarters · filed 2026-08-03
$53.92M
10-K · filed 2026-02-05
2025-09-30$13.09M
10-Q · filed 2025-11-04
$26.82M
derived: sum of 2 quarters · filed 2026-08-03
$40.97M
10-Q · filed 2025-11-04
$51.80M
derived: sum of 4 quarters · filed 2026-08-03
2025-06-30$13.73M
10-Q · filed 2026-08-03
$27.88M
10-Q · filed 2026-08-03
$38.72M
derived: sum of 3 quarters · filed 2026-08-03
$49.29M
derived: sum of 4 quarters · filed 2026-08-03
2025-03-31$14.15M
10-Q · filed 2026-05-05
$24.99M
derived: sum of 2 quarters · filed 2026-05-05
$35.56M
derived: sum of 3 quarters · filed 2026-05-05
$45.55M
derived: sum of 4 quarters · filed 2026-05-05
2024-12-31$10.84M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05
$21.41M
derived: sum of 2 quarters · filed 2026-02-05
$31.41M
derived: sum of 3 quarters · filed 2026-02-05
$41.59M
10-K · filed 2026-02-05
2024-09-30$10.57M
10-Q · filed 2025-11-04
$20.57M
derived: sum of 2 quarters · filed 2025-11-04
$30.75M
10-Q · filed 2025-11-04
$39.99M
derived: sum of 4 quarters · filed 2026-02-05
2024-06-30$9.99M
10-Q · filed 2025-08-05
$20.18M
10-Q · filed 2025-08-05
$29.42M
derived: sum of 3 quarters · filed 2026-02-05
$38.74M
derived: sum of 4 quarters · filed 2026-02-05
2024-03-31$10.18M
10-Q · filed 2025-05-05
$19.43M
derived: sum of 2 quarters · filed 2026-02-05
$28.74M
derived: sum of 3 quarters · filed 2026-02-05
$39.90M
derived: sum of 4 quarters · filed 2026-02-05
2023-12-31$9.24M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05
$18.56M
derived: sum of 2 quarters · filed 2026-02-05
$29.71M
derived: sum of 3 quarters · filed 2026-02-05
$40.55M
10-K · filed 2026-02-05
2023-09-30$9.31M
10-Q · filed 2024-11-14
$20.47M
derived: sum of 2 quarters · filed 2024-11-14
$31.30M
10-Q · filed 2024-11-14
$41.84M
derived: sum of 4 quarters · filed 2025-03-03
2023-06-30$11.15M
10-Q · filed 2024-08-07
$21.99M
10-Q · filed 2024-08-07
$32.52M
derived: sum of 3 quarters · filed 2025-03-03
$42.71M
derived: sum of 4 quarters · filed 2025-03-03
2023-03-31$10.84M
10-Q · filed 2024-05-07
$21.37M
derived: sum of 2 quarters · filed 2025-03-03
$31.55M
derived: sum of 3 quarters · filed 2025-03-03
$41.69M
derived: sum of 4 quarters · filed 2025-03-03
2022-12-31$10.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03
$20.72M
derived: sum of 2 quarters · filed 2025-03-03
$30.86M
derived: sum of 3 quarters · filed 2025-03-03
$39.92M
10-K · filed 2025-03-03
2022-09-30$10.19M
10-Q · filed 2023-11-07
$20.33M
derived: sum of 2 quarters · filed 2023-11-07
$29.39M
10-Q · filed 2023-11-07
$38.52M
derived: sum of 4 quarters · filed 2024-03-11
2022-06-30$10.14M
10-Q · filed 2023-08-07
$19.20M
10-Q · filed 2023-08-07
$28.34M
derived: sum of 3 quarters · filed 2024-03-11
$37.91M
derived: sum of 4 quarters · filed 2024-03-11
2022-03-31$9.06M
10-Q · filed 2023-05-08
$18.20M
derived: sum of 2 quarters · filed 2024-03-11
$27.77M
derived: sum of 3 quarters · filed 2024-03-11
$36.17M
derived: sum of 4 quarters · filed 2024-03-11
2021-12-31$9.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11
$18.71M
derived: sum of 2 quarters · filed 2024-03-11
$27.10M
derived: sum of 3 quarters · filed 2024-03-11
$35.19M
10-K · filed 2024-03-11
2021-09-30$9.58M
10-Q · filed 2022-11-07
$17.97M
derived: sum of 2 quarters · filed 2022-11-07
$26.05M
10-Q · filed 2022-11-07
$32.86M
derived: sum of 4 quarters · filed 2023-03-06
2021-06-30$8.39M
10-Q · filed 2022-08-08
$16.48M
10-Q · filed 2022-08-08
$23.29M
derived: sum of 3 quarters · filed 2023-03-06
$29.81M
derived: sum of 4 quarters · filed 2023-03-06
2021-03-31$8.09M
10-Q · filed 2022-05-09
$14.90M
derived: sum of 2 quarters · filed 2023-03-06
$21.42M
derived: sum of 3 quarters · filed 2023-03-06
$27.57M
derived: sum of 4 quarters · filed 2023-03-06
2020-12-31$6.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06
$13.33M
derived: sum of 2 quarters · filed 2023-03-06
$19.48M
derived: sum of 3 quarters · filed 2023-03-06
$26.61M
10-K · filed 2023-03-06
2020-09-30$6.52M
10-Q · filed 2021-11-08
$12.67M
derived: sum of 2 quarters · filed 2021-11-08
$19.80M
10-Q · filed 2021-11-08
$26.95M
derived: sum of 4 quarters · filed 2022-02-28
2020-06-30$6.15M
10-Q · filed 2021-08-09
$13.28M
10-Q · filed 2021-08-09
$20.43M
derived: sum of 3 quarters · filed 2022-02-28
$27.20M
derived: sum of 4 quarters · filed 2022-02-28
2020-03-31$7.13M
10-Q · filed 2021-05-05
$14.27M
derived: sum of 2 quarters · filed 2022-02-28
$21.05M
derived: sum of 3 quarters · filed 2022-02-28
$28.27M
derived: sum of 4 quarters · filed 2022-02-28
2019-12-31$7.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28
$13.92M
derived: sum of 2 quarters · filed 2022-02-28
$21.14M
derived: sum of 3 quarters · filed 2022-02-28
$24.49M
10-K · filed 2022-02-28
2019-09-30$6.78M
10-Q · filed 2020-11-05
$14.00M
derived: sum of 2 quarters · filed 2020-11-05
$17.35M
10-Q · filed 2020-11-05
$19.64M
derived: sum of 4 quarters · filed 2020-11-05
2019-06-30$7.22M
10-Q · filed 2020-08-07
$10.57M
10-Q · filed 2020-08-07
$12.86M
derived: sum of 3 quarters · filed 2020-08-07
$13.93M
derived: sum of 4 quarters · filed 2020-08-07
2019-03-31$3.35M
10-Q · filed 2020-05-08
$5.64M
derived: sum of 2 quarters · filed 2020-05-08
$6.71M
derived: sum of 3 quarters · filed 2020-05-08
$7.57M
derived: sum of 4 quarters · filed 2020-05-08
2018-12-31$2.29M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$3.36M
derived: sum of 2 quarters · filed 2020-03-12
$4.22M
derived: sum of 3 quarters · filed 2020-03-12
$4.94M
10-K · filed 2020-03-12
2018-09-30$1.07M
10-Q · filed 2019-11-12
$1.93M
derived: sum of 2 quarters · filed 2019-11-12
$2.65M
10-Q · filed 2019-11-12
$3.55M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30$867.00K
10-Q · filed 2019-08-07
$1.58M
10-Q · filed 2019-08-07
$2.49M
derived: sum of 3 quarters · filed 2020-03-12
$5.72M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$717.00K
10-Q · filed 2019-05-10
$1.62M
derived: sum of 2 quarters · filed 2020-03-12
$4.86M
derived: sum of 3 quarters · filed 2020-03-12
$11.69M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31$903.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$4.14M
derived: sum of 2 quarters · filed 2020-03-12
$10.97M
derived: sum of 3 quarters · filed 2020-03-12
$17.00M
10-K · filed 2020-03-12
2017-09-30$3.24M
10-Q · filed 2018-11-07
$10.07M
derived: sum of 2 quarters · filed 2018-11-07
$16.10M
10-Q · filed 2018-11-07
$18.62M
derived: sum of 4 quarters · filed 2019-03-07
2017-06-30$6.83M
10-Q · filed 2018-08-07
$12.86M
10-Q · filed 2018-08-07
$15.38M
derived: sum of 3 quarters · filed 2019-03-07
$16.68M
derived: sum of 4 quarters · filed 2019-03-07
2017-03-31$6.03M
10-Q · filed 2018-05-08
$8.55M
derived: sum of 2 quarters · filed 2019-03-07
$9.85M
derived: sum of 3 quarters · filed 2019-03-07
$11.34M
derived: sum of 4 quarters · filed 2019-03-07
2016-12-31$2.53M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
$3.82M
derived: sum of 2 quarters · filed 2019-03-07
$5.31M
derived: sum of 3 quarters · filed 2019-03-07
$6.70M
10-K · filed 2019-03-07
2016-09-30$1.29M
10-Q · filed 2017-11-07
$2.79M
derived: sum of 2 quarters · filed 2017-11-07
$4.17M
10-Q · filed 2017-11-07
$5.32M
derived: sum of 4 quarters · filed 2018-03-08
2016-06-30$1.49M
10-Q · filed 2016-08-09
$2.88M
10-Q · filed 2017-08-08
$4.02M
derived: sum of 3 quarters · filed 2018-03-08
$4.82M
derived: sum of 4 quarters · filed 2018-03-08
2016-03-31$1.39M
10-Q · filed 2017-05-05
$2.53M
derived: sum of 2 quarters · filed 2018-03-08
$3.33M
derived: sum of 3 quarters · filed 2018-03-08
$4.37M
derived: sum of 4 quarters · filed 2018-03-08
2015-12-31$1.14M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08
$1.94M
derived: sum of 2 quarters · filed 2018-03-08
$2.98M
derived: sum of 3 quarters · filed 2018-03-08
$3.85M
10-K · filed 2018-03-08
2015-09-30$798.00K
10-Q · filed 2016-11-09
$1.84M
derived: sum of 2 quarters · filed 2016-11-09
$2.71M
10-Q · filed 2016-11-09
$3.37M
derived: sum of 4 quarters · filed 2017-03-10
2015-06-30$1.04M
10-Q · filed 2016-08-09
$1.91M
10-Q · filed 2016-08-09
$2.57M
derived: sum of 3 quarters · filed 2017-03-10
$3.05M
derived: sum of 4 quarters · filed 2017-03-10
2015-03-31$870.00K
10-Q · filed 2016-05-10
$1.53M
derived: sum of 2 quarters · filed 2017-03-10
$2.01M
derived: sum of 3 quarters · filed 2017-03-10
$2.54M
derived: sum of 4 quarters · filed 2017-03-10
2014-12-31$658.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-10
$1.14M
derived: sum of 2 quarters · filed 2017-03-10
$1.67M
derived: sum of 3 quarters · filed 2017-03-10
$1.98M
10-K · filed 2017-03-10
2014-09-30$479.00K
10-Q · filed 2015-11-10
$1.01M
derived: sum of 2 quarters · filed 2015-11-10
$1.32M
10-Q · filed 2015-11-10
$1.52M
derived: sum of 4 quarters · filed 2016-03-10
2014-06-30$535.00K
10-Q · filed 2015-08-10
$845.00K
10-Q · filed 2015-08-10
$1.04M
derived: sum of 3 quarters · filed 2016-03-10
$1.19M
derived: sum of 4 quarters · filed 2016-03-10
2014-03-31$310.00K
10-Q · filed 2015-05-15
$507.00K
derived: sum of 2 quarters · filed 2016-03-10
$655.00K
derived: sum of 3 quarters · filed 2016-03-10
$798.00K
derived: sum of 4 quarters · filed 2016-03-10
2013-12-31$197.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-10
$345.00K
derived: sum of 2 quarters · filed 2016-03-10
$488.00K
derived: sum of 3 quarters · filed 2016-03-10
$625.00K
10-K · filed 2016-03-10
2013-09-30$148.00K
10-Q · filed 2014-11-12
$291.00K
derived: sum of 2 quarters · filed 2014-11-12
$428.00K
10-Q · filed 2014-11-12
2013-06-30$143.00K
10-Q · filed 2014-08-29
$280.00K
10-Q · filed 2014-08-29
2012-12-31$657.00K
10-K · filed 2015-03-20

Similar stocks

Stock NameCountryMarket CapPE Ratio
Prestige Consumer Healthcare Inc. (PBH)United States$2.163B13.03
Bausch Health Companies Inc. (BHC)$2.113B-1.68
Aurinia Pharmaceuticals Inc. (AUPH)$2.207B7.18
Braveheart Bio, Inc. (BRVE)United States$2.106B
PALVELLA THERAPEUTICS, INC. (PVLA)United States$2.105B-35.55
Trevi Therapeutics, Inc. (TRVI)United States$2.091B-51.93
Zai Lab Ltd (ZLAB)$2.241B-113.34
Generate Biomedicines, Inc. (GENB)United States$2.052B
PERRIGO Co plc (PRGO)Ireland$2.038B-0.79
NEKTAR THERAPEUTICS (NKTR)United States$2.026B-9.05